Navigation Links
Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
Date:5/8/2012

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- The new prescription sleep aid Intermezzo (zolpidem tartrate) sublingual tablet CIV is the first and only prescription sleep aid approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep, and the patient has at least four hours of bedtime remaining before the planned time of waking. Intermezzo has gender-specific dosing (1.75 mg for adult women and 3.5 mg for adult men) taken only once per night as needed if a middle-of-the-night awakening is followed by difficulty returning to sleep. Intermezzo 1.75 mg is also the recommended dose for men and women over 65 years of age, patients with hepatic impairment, or patients taking concomitant CNS depressants.

In the double-blind, placebo-controlled, cross-over pharmacokinetic study in healthy volunteers, Intermezzo doses of 1.0 mg, 1.75 mg, and 3.5 mg were administered on two consecutive days to 11 women and 13 men. At the same dose, the plasma levels of zolpidem tartrate in women were approximately 45 percent higher than in men. The study found that women taking a 3.5 mg dose cleared the drug at a slower rate than men taking 3.5 mg (2.7 ml/min/kg vs. 4.00 ml/min/kg, respectively).

"Given that women clear the active ingredient in Intermezzo at a lower rate than men, the results of the study support a recommended lower dosage of Intermezzo for women and a higher dosage for men," said study co-author Thomas Roth, Ph.D., Director of Sleep Medicine at Henry Ford Hospital in Detroit.

Intermezzo was approved by the FDA in November 2011 and is available nationwide in spearmint-flavored sublingual tablets that are placed under the tongue and allowed to disintegrate completely before swallowing. Intermezzo contains a bicarbonate-carbonate buffer. On average, Intermezzo is rapidly absorbed in both genders, achieving peak mean plasma levels of zolpidem in
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
5. 12 Month TRAM Data Collated Using TIGR® Matrix Surgical Mesh in a Randomized Controlled Study Presented at MAPACS 2012
6. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
7. Frost & Sullivan New Product Innovation Award Presented to Brainsway for Its Deep Transcranial Magnetic Stimulation (dTMS) Device
8. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
9. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
10. nContacts Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... BURLINGTON, Mass. , May 21, 2013 ... leading research and advisory firms for pharmaceutical ... of an emerging agent on key efficacy ... disease progression, has the most influence over ... for advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast ...
(Date:5/21/2013)... CLARA, Calif. , May 21, 2013 ... game-changing embedded-ultrasound platform, today announced the introduction ... that allows complete network-based communications with all ... its latest embedded-ultrasound technology, including this new ... Sao Paulo, Brazil from ...
(Date:5/21/2013)... 21, 2013  The North Shore-LIJ Health System is ... hand-washing compliance at North Shore University Hospital in ... operating rooms at Forest Hills ... The new pilot program strengthens patient safety by ... (ORs), the first time in the US that remote ...
Breaking Medicine Technology:Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4
... June 1, 2011 Mirixa Corporation is pleased to ... licensing agreement for MirixaEdge(SM), a clinical application that supports ... Medication Therapy Management (MTM). Family Physicians Group (FPG), ... Source Pharmacy and selected it as FPG,s preferred pharmacy ...
... YORK, June 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0305172/Global-Intravenous-IV-Iron-Drugs-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... Intravenous (IV) Iron Drugs in US$ Million. ...
Cached Medicine Technology:MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 2MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 3Global Intravenous (IV) Iron Drugs Industry 2Global Intravenous (IV) Iron Drugs Industry 3Global Intravenous (IV) Iron Drugs Industry 4Global Intravenous (IV) Iron Drugs Industry 5Global Intravenous (IV) Iron Drugs Industry 6Global Intravenous (IV) Iron Drugs Industry 7
(Date:5/21/2013)... May 2013 EMBO announced today that 52 outstanding ... its membership. Forty-three of the researchers reside in Europe ... of nine Associate Members from Canada, China, India, Japan ... around 1600 life scientists. , "Our members are the ... Director Maria Leptin said. "We have been building our ...
(Date:5/21/2013)... GA (PRWEB) May 21, 2013 ... ScripNet and Procura Management, today announced that it ... at Catamaran’s client advisory meeting. Conferred annually, ... partnered with Catamaran to create cutting edge programs ... year, Healthcare Solutions was recognized for its clinical ...
(Date:5/21/2013)... New York, NY (PRWEB) May 21, 2013 ... leukemia, melanoma or non-small cell lung cancer reported that ... behavior in their medicine use, according to new findings ... (NHWS), conducted by Kantar Health . The research ... Meeting for ISPOR (International Society for Pharmacoeconomics and Outcomes ...
(Date:5/21/2013)... A plastic surgery Internet marketing ... surgery SEO services following an Internet survey. , ... the “Best Plastic Surgery SEO Services”. , Sources ... predictable. Well-known in the plastic surgery Internet marketing ... any other selection based on superior client results. ...
(Date:5/21/2013)... It’s nearly summer and millions of kids will soon be ... or fall sports. In many cases a physical exam ... , To help parents during this busy time, MedSpring is ... physicals at just $29. As part of the ... perform a physical exam and complete required forms. Patients can ...
Breaking Medicine News(10 mins):Health News:EMBO announces 52 new members for 2013 2Health News:Healthcare Solutions Receives Innovation Award From Catamaran 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2
... of his other colleagues in the industry with his huge list ... his tour of Europe. ,A source said that ... the tablets are quite difficult to get in Europe. ... are difficult to get in Europe," the Sun quoted the source, ...
... to a new review of studies,doctors are famous for ... of medication errors each year. Electronics to the ... entry systems saw a 66 percent drop in prescription ... are responsible for as much as 61 percent of ...
... Gullotta, said today that the review of childrens television standards by ... a ban on junk food advertising in childrens TV viewing times. ... to the ACMA review and he urged all groups concerned with ... ban on junk food advertising to kids must be a priority ...
... version of a molecule found in the egg cells of ... with the first drug treatment for brain tumours. ... tumour cell and binds to its surface before invading the ... to die. ,In new research published in the ...
... has found that fishes use the threat of punishment ... line and the social order stable. ,Their ... humans, has been hailed by some of the worlds leading ... the Proceedings of the Royal Society of London Series B. ...
... and soft drinks, may seem like harmless snacks and beverages, ... permanent damage to teeth. ,Its known as ... the effect of acid on the teeth that leads to ... of tooth erosion are fundamental to keeping teeth healthy for ...
Cached Medicine News:Health News:Computerized Doctors Order Reduce Prescription Errors 2Health News:Computerized Doctors Order Reduce Prescription Errors 3Health News:Brain Tumor Drug in Frogs A New Report 2Health News:Fishes Use Threat of Punishment in Mating Process 2Health News:Too Much of Acidic Foods can Cause Permanent Damage to Teeth 2
... Quinton Q-Track II Holter Monitoring System uses ... produced the worlds first true 12-lead digital ... presentation of any beat contained in the ... , ,The preprocessing work done by the ...
... an automatic petri dish streaking machine. ... up to 180 pre inoculated petri ... in substantial cost savings. The ISOPLATER® ... standardizes streaking procedures and increases safety ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
Medicine Products: